Structured evidence table for Sea Buckthorn Blood Lipids Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Sea Buckthorn Blood Lipids Randomized Trial | Review approach: This review covers studies on fatty acid composition, minor bioactive compounds, antioxidant and anti-inflammatory activities, lipid metabolism-related effects, and the valorization of processing by-products, with evidence primarily derived from in vitro and in vivo studies. | 3 | Jiang X (2026) | From Nutritional Profile to Circular Bioeconomy: A Review of Sea Buckthorn Oil and By-Product Valorization. |
| Sea Buckthorn Blood Lipids Randomized Trial | However, current evidence is largely based on experimental studies, and further research is needed to clarify the mechanisms of action, bioavailability, dose-response relationships, and clinical efficacy. | 3 | Jiang X (2026) | From Nutritional Profile to Circular Bioeconomy: A Review of Sea Buckthorn Oil and By-Product Valorization. |
| Sea Buckthorn Blood Lipids Randomized Trial | Background This review summarizes the current knowledge on the composition, bioactive constituents, health-related effects, and by-product utilization of sea buckthorn ( Hippophaë rhamnoides L.) seed and pulp oils. | 3 | Jiang X (2026) | From Nutritional Profile to Circular Bioeconomy: A Review of Sea Buckthorn Oil and By-Product Valorization. |
| Sea Buckthorn Blood Lipids Randomized Trial | This narrative review integrates observational, clinical, and mechanistic evidence across circulating lipids and lipoproteins, glucose homeostasis, inflammation and vascular markers, adiposity, and hepatic endpoints. | 3 | Destaillats F (2026) | Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. |
| Sea Buckthorn Blood Lipids Randomized Trial | Overall, current evidence supports cautious interpretation: POA is biologically interesting, but clinically meaningful benefits of purified POA supplementation remain unproven and require adequately powered trials in well-characterized at-risk populations. | 3 | Destaillats F (2026) | Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. |
| Sea Buckthorn Blood Lipids Randomized Trial | Palmitoleic acid (POA; 16:1 n-7) has been proposed as a lipokine linking adipose tissue, liver, and skeletal muscle metabolism, but its relevance to human metabolic health remains uncertain. | 3 | Destaillats F (2026) | Palmitoleic (16:1 n-7) acid and metabolic health: integrating observational, clinical, and mechanistic evidence. |
Source documents